<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00658346</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12168 DYNA M-O</org_study_id>
    <nct_id>NCT00658346</nct_id>
  </id_info>
  <brief_title>Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon</brief_title>
  <official_title>Molecular Diversity of HIV-1 Group O Strains and Treatment Management in Cameroon</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections with HIV-1 group O are found in 1 to 3 % of persons living with HIV in Cameroon.
      The natural history and treatment response is not well understood. The natural resistance to
      non nucleoside reverse transcriptase inhibitors and their possible low sensitivity to
      protease inhibitors complicate the choice of an adequate treatment options.

      This observational study is aimed at evaluating the antiretroviral treatment response of
      HIV-1 group O infected patients in comparison with HIV-1 group M infected patients. The
      proposed standardized follow-up will facilitate a better understanding of the natural history
      and treatment specificities to improve the patients management.

      This is a non randomized study, open label, with standardized follow-up. A total of 171
      patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with plasmatic HIV viral load bellow 60 copies / ml</measure>
    <time_frame>48 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with plasmatic HIV viral load bellow 60 copies / ml</measure>
    <time_frame>24 and 96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early and late slope of viral load decrease</measure>
    <time_frame>between weeks 2 and 12, and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early and late slope of CD4 counts increase</measure>
    <time_frame>between weeks 2 and 12, and week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with a stabilized CD4 counts gain over 50%</measure>
    <time_frame>96 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virological failure</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resistance mutation profile when virological failure</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evaluation : proportion of adverse events, AIDS related events, deaths, morphologic modification</measure>
    <time_frame>Through out the trial</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">141</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>HIV-1 group O infected patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>HIV-1 group M infected patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment initiation for HIV-1 group O infected patients</intervention_name>
    <description>The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
If Hb &gt; 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)
If Hb &lt;= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)
If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment initiation for HIV-1 group M infected patients</intervention_name>
    <description>The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
If Hb &gt; 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)
If Hb &lt;= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)
If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma and mononucleus cells
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-1 infected patients coming for medical care in four treatment centers in Yaounde.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 group O or group M infection

          -  No history of antiretroviral treatment (except for PMTCT)

          -  Criteria for treatment initiation according to the Cameroons national guidelines

        Exclusion Criteria:

          -  Ongoing traditional treatment which could interfere with hepatic function

          -  Ongoing treatment with rifabutin, rifampicin or rifampin

          -  Acute hepatitis B infection

          -  Pregnancy or lactating mother

          -  HIV-1 group O and group M co-infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Central</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de la CNPS</name>
      <address>
        <city>Yaounde</city>
        <country>Cameroon</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Cameroon</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2008</study_first_submitted>
  <study_first_submitted_qc>April 14, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 15, 2008</study_first_posted>
  <last_update_submitted>January 11, 2017</last_update_submitted>
  <last_update_submitted_qc>January 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV-1 group O</keyword>
  <keyword>HIV-1 group M</keyword>
  <keyword>Cameroon</keyword>
  <keyword>HIV-1 infection</keyword>
  <keyword>treatment naïve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

